Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Accumulated Expenses (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Accumulated Expenses for 16 consecutive years, with $11.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses rose 23.51% to $11.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $11.8 million, a 23.51% increase, with the full-year FY2024 number at $10.6 million, down 11.06% from a year prior.
  • Accumulated Expenses was $11.8 million for Q3 2025 at Gyre Therapeutics, down from $14.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $14.9 million in Q2 2025 to a low of $180000.0 in Q4 2021.
  • A 5-year average of $5.5 million and a median of $2.5 million in 2021 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: tumbled 92.73% in 2021, then skyrocketed 5046.67% in 2022.
  • Gyre Therapeutics' Accumulated Expenses stood at $180000.0 in 2021, then surged by 5046.67% to $9.3 million in 2022, then grew by 28.83% to $11.9 million in 2023, then decreased by 11.06% to $10.6 million in 2024, then rose by 11.15% to $11.8 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Accumulated Expenses are $11.8 million (Q3 2025), $14.9 million (Q2 2025), and $10.6 million (Q4 2024).